STAT+: FDA warns more telehealth firms about compounded GLP-1sSTAT+: FDA warns more telehealth firms about compounded GLP-1s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Moderna is avoiding what would have been a high-profile trial, but will still have to pay up. That and more news below. Let’s get to it. Moderna to pay major settlement in Read More
AI could help us more accurately screen for breast cancer—new researchAI could help us more accurately screen for breast cancer—new research
At least 20,000 Australian women are diagnosed with breast cancer each year. And more than 3,300 die from the disease. To save women’s lives, we need to detect breast cancer early. Breast screening, which halves women’s risk of dying from breast cancer, is key to that.
Work exploring role of the mannose pathway in regulating cell fate decisions may hold promise for cancer therapyWork exploring role of the mannose pathway in regulating cell fate decisions may hold promise for cancer therapy
A research team has conducted a study exploring the role of the mannose pathway in regulating cell fate decisions in low glucose environments. Their work may hold potential for novel therapeutic strategies in cancer treatments. The research is published in the Journal of Biological Chemistry.
FDA Warns 30 Telehealth Firms Over Compounded GLP-1 MedicationsFDA Warns 30 Telehealth Firms Over Compounded GLP-1 Medications
(MedPage Today) — Thirty warning letters were issued to telehealth companies for false and misleading claims about compounded GLP-1 receptor agonist products, the FDA announced on Tuesday. The letters primarily targeted claims implying “sameness… (MedPage Today) — Thirty warning letters were issued to telehealth companies for false and misleading claims about compounded GLP-1 receptor Read More
GLP-1 drugs may cut risk of major heart complications after heart attackGLP-1 drugs may cut risk of major heart complications after heart attack
Weight-loss (GLP-1 mimicking) drugs may help prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications that affect up to half of all patients, according to a new study led by the University of Bristol and University College London (UCL). Weight-loss (GLP-1 mimicking) drugs may help prevent further tissue Read More
High-fat diet accelerates triple-negative breast cancer growth in engineered tumorsHigh-fat diet accelerates triple-negative breast cancer growth in engineered tumors
A multidisciplinary team of researchers at Princeton University conducted a study to find out what patients diagnosed with breast cancer should eat to ensure the best prognosis. “We took the approach of building identical engineered tumors and culturing them in conditions that mimic the blood composition of patients under different dietary states,” author Celeste M. Nelson said. “We were hoping to identify dietary conditions that would slow tumor growth. Instead, we found one dietary condition—a high-fat diet—that sped up tumor growth.”
SGLT2 Inhibitors May Lead to Better Kidney Outcomes Than GLP-1 DrugsSGLT2 Inhibitors May Lead to Better Kidney Outcomes Than GLP-1 Drugs
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower risk of adverse kidney outcomes than glucagon-like peptide-1 (GLP-1) receptor agonists in people with type 2 diabetes in a recent study that emulated a clinical trial. Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower risk of adverse kidney outcomes than glucagon-like peptide-1 (GLP-1) receptor agonists Read More
Risk-Based vs Annual Breast Cancer ScreeningRisk-Based vs Annual Breast Cancer Screening
This randomized clinical trial examines whether risk-based screening is a safe and effective alternative to annual mammography for detecting breast cancer in women 40 years and older.
Unlocking the Potential of Risk-Based Screening for Breast CancerUnlocking the Potential of Risk-Based Screening for Breast Cancer
Breast cancer is the most frequently diagnosed malignant neoplasm among women in the US and remains a leading cause of cancer mortality. In 2025, an estimated 316 950 women were diagnosed with invasive disease and 42 170 died, reflecting a lifetime risk of approximately 1 in 8. These patterns in breast cancer morbidity and mortality underscore the continued need for advances in prevention, screening, and treatment.
Risk-Based vs Annual Breast Cancer Screening Research SummaryRisk-Based vs Annual Breast Cancer Screening Research Summary
This trial aimed to assess whether risk-based screening is as safe, less morbid, and as acceptable to women as annual screening for breast cancer detection.